Table 1.

Content and subtheme analysis of systematic review

Headings	Specific questions
1. Clinical relevance of HbA1c in monitoring	(a) HbA1c limit should be set person to person rather than a generalized limit.
	(b) Use A1c and other variables along with CGM for more accurate results.
	(c) HbA1c values have limitations.
2. Clinical controversies of HbA1c	(a) Discrepancy b/w calculated eA1c and HbA1c. (b) SMBG fails to detect nocturnal and asymptomatic hypoglycemia (sporadic nature).
	(c) Hypoglycemia is not regularly measured when you are using HBA1c.
3. CGM used in TD1 than TD2	(a) Use of CGM in patients with TD1 causes a major decrease in the HbA1c levels.
	(b) Lack of studies for TD2: More real-time data needed because helpful for TD2.
4. Limitations of CGM in clinical practice	(c) Insufficient data for adjustment of treatment regimen.
	(d) For patients on oral therapy or insulin therapy, hypoglycemia measurement is EVEN MORE important.
	(e) CGM is expensive, hence limited use.
5. Patient perception on CGM	(f) Patient inconvenience with SMBG vs. CGM.
	(g) CGM is user friendly.
	(h) CGM is less time consuming.
6. Future implications of CGM	(i) Pregnant women with diabetes mellitus also benefit from CGM.
	(j) Comorbidities should be considered: Not enough studies on comorbidities.
	(k) May be used for TD2 for therapy decisions.
	(l) How involved insurance companies will be?
7. Glucose variability	Literature reported

HbA1c = glycated hemoglobin, CGM = continuous glucose monitoring, TD1 = type 1 diabetes mellitus, TD2 = type 2 diabetes mellitus, eA1c = estimated A1C, SMBG = self-monitoring of blood glucose